论文部分内容阅读
目的探讨短期(3个月)重组甘精胰岛素+三餐阿卡波糖强化治疗对新诊断的T2DM患者胰岛β细胞功能及血糖控制的影响。方法采用自身前后对照的方法,对60例新诊断但未治疗的T2DM患者给予3个月重组甘精胰岛素+阿卡波糖强化治疗,治疗前后分别行静脉葡萄糖耐量试验(IVGTT),计算0～10min时胰岛素曲线下面积(AUC_(0～10))、1～3min急性胰岛素对葡萄糖的分泌反应(AIR_(1～3))、胰岛素分泌指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)的变化。结果治疗后IVGTT试验的AUC_(0～10)、AIR_(1～3)及HOMA-β较试验前明显增加,而空腹及餐后血糖、HbA_1c、HOMA-IR较治疗前明显下降。结论新诊断的T2DM患者接受短期甘精胰岛素+阿卡波糖治疗使血糖快速、安全达标的同时显著改善胰岛β细胞功能和胰岛素敏感性,治疗简便,依从性较高。
Objective To investigate the effect of short-term (3 months) recombinant insulin glargine + three-acupuncture on pancreatic β-cell function and glycemic control in newly diagnosed T2DM patients. Methods 60 cases of newly diagnosed but untreated T2DM patients were given 3 months of recombinant glargine plus acarbose for intensive treatment by means of their own front and back control. Before and after treatment, intravenous glucose tolerance test (IVGTT) The area under the curve of insulin (AUC_ (0 ~ 10) at 10min), the secretion of glucose (AIR_ (1-3)), insulin secretion index (HOMA-β) and insulin resistance index (HOMA-IR )The change. Results The AUC_ (0 ~ 10), AIR_ (1 ~ 3) and HOMA-β in IVGTT test were significantly increased after treatment, but the fasting and postprandial blood glucose, HbA_1c and HOMA-IR were significantly lower than those before treatment. Conclusions The newly diagnosed T2DM patients receiving short-term insulin glargine plus acarbose treatment have fast and safe blood glucose, significantly improved pancreatic β-cell function and insulin sensitivity, and have the advantages of simple treatment and high compliance.